Clinical trials: Neuroendocrine Tumor Metastatic
Pheochromocytoma and Paraganglioma (PPGL), Pheochromocytoma Malignant
An Experimental Study of Belzutifan Impact on Catecholamine Metabolism
To investigate the impact of a medication called Belzutifan on the production and subsequent metabolism of adrenaline and noradrenaline collectively termed 'catecholamines'.
- Conditions
- Pheochromocytoma and Paraganglioma (PPGL), Pheochromocytoma Malignant, Pheochromocytoma, Metastatic, Pheochromocytoma/Paraganglioma
- Trial name
- NCT07680205
- Testing
- Belzutifan
- Where
- United Kingdom
- Volunteers
- 12 people
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
Mesothelioma, Glioblastoma
Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies
Study of NGM707 as Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies
- Conditions
- Mesothelioma, Glioblastoma, Renal Cell Carcinoma, Non Small Cell Lung Cancer
- Trial name
- NCT04913337
- Testing
- NGM707, NGM707 plus pembrolizumab (KEYTRUDA®)
- Where
- 27 sites in United States, South Korea and 1 more
- Volunteers
- 179 people
- Sponsor
- NGM Biopharmaceuticals, Inc
Locally Advanced or Metastatic Melanoma
Study of CBL0137 in Combination With Ipilimumab and Nivolumab Therapy in Melanoma
Phase I, open label, dose-escalation, and safety study designed to assess the safety and biologic activity of the investigational agent CBL0137 in combination with standard of care drugs, ipilimumab and nivolumab in sequential…
- Trial name
- NCT05498792
- Testing
- CBL0137, Ipilimumab, Nivolumab
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Fox Chase Cancer Center
Metastatic Melanoma
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma
Background: The National Cancer Institute (NCI) Surgery Branch has developed an experimental therapy that involves taking white blood cells from patients' tumors, growing them in the laboratory in large numbers, and then giving…
- Trial name
- NCT01993719
- Testing
- Aldesleukin, Fludarabine, Cyclophosphamide
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- National Cancer Institute (NCI)
Ocular Melanoma, Uveal Melanoma
Percutaneous Hepatic Perfusion in Patients With Hepatic-dominant Ocular Melanoma
This study will evaluate patients who have ocular melanoma that has spread from the eye to the liver: Patients in the study will be treated with Melphalan/HDS up to 6 total treatments and will be followed until death.
- Trial name
- FOCUS (NCT02678572)
- Testing
- Melphalan/HDS
- Where
- 22 sites in United States, Austria and 7 more
- Volunteers
- 102 people
- Sponsor
- Delcath Systems Inc.
Urothelial Carcinoma, Head and Neck Cancer
MAGE-A10ᶜ⁷⁹⁶T for Urothelial Cancer, Melanoma or Head and Neck Cancers
This Phase 1 study is designed as a cell dose escalation trial in HLA-A*02:01 and HLA-A*02:06 subjects with MAGE-A10 positive urothelial, melanoma or head and neck tumors.
- Conditions
- Urothelial Carcinoma, Head and Neck Cancer, Melanoma, Bladder Urothelial Carcinoma
- Trial name
- NCT02989064
- Testing
- Autologous genetically modified MAGE A10ᶜ⁷⁹⁶T cells
- Where
- 11 sites in United States, Canada and 1 more
- Volunteers
- 10 people
- Sponsor
- Adaptimmune
Neuroendocrine Tumors
Lutathera and ASTX727 in Neuroendocrine Tumours
Patients entered into the study will receive ASTX727 orally for 5 days, prior to receiving Lutathera treatment on Day 8, to determine whether pre-treatment with ASTX727 results in re-expression of somatostatin receptor-2 in…
- Trial name
- LANTana (NCT05178693)
- Testing
- ASTX727, Lutathera
- Where
- United Kingdom
- Volunteers
- 27 people
- Sponsor
- Imperial College London
Metastatic Melanoma, Recurrent Cutaneous Melanoma
Ibrutinib in Treating Patients With Refractory Metastatic Cutaneous Melanoma
This phase II trial studies how well ibrutinib works in treating patients with stage IV melanoma of the skin that has not responded to previous treatment.
- Conditions
- Metastatic Melanoma, Recurrent Cutaneous Melanoma, Stage IV Cutaneous Melanoma AJCC v6 and v7
- Trial name
- NCT02581930
- Testing
- Ibrutinib, Laboratory Biomarker Analysis, Pharmacogenomic Study
- Where
- 13 sites in United States
- Volunteers
- 18 people
- Sponsor
- National Cancer Institute (NCI)
Brain Tumour, Glioma
Use of Non-invasive Optical Analysis in Neurosurgery
The present study aims to investigate the potential application of multispectral analysis, hyperspectral imaging, and fluorescence during neuro-oncological procedures, specifically during brain tumour debulking / resection.
- Conditions
- Brain Tumour, Glioma, Meningioma, Brain Metastases
- Trial name
- NCT04712214
- Testing
- Intra-operative multispectral / hyperspectral analysis
- Where
- United Kingdom
- Volunteers
- 50 people
- Sponsor
- Imperial College London
Cutaneous Squamous Cell Carcinoma, SCC - Squamous Cell Carcinoma
A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
Participants of this study will have a diagnosis of a solid tumor cancer that has come back to its original location or spread beyond its original location (advanced), came back (relapsed) or worsened (refractory) after standard…
- Conditions
- Cutaneous Squamous Cell Carcinoma, SCC - Squamous Cell Carcinoma, Basal Cell Carcinoma, BCC
- Trial name
- NCT05859074
- Testing
- MQ719, Pembrolizumab
- Where
- 7 sites in United States
- Volunteers
- 56 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Metastatic Melanoma
A Study to Compare How Effective is Encorafenib Plus Binimetinib in Real-world and Clinical Trial Settings
Brief summary The purpose of this study is to compare how effective, encorafenib plus binimetinib is in the real-world and clinical trial settings.
- Trial name
- NCT05954546
- Testing
- Enco+bini
- Where
- United States
- Volunteers
- 275 people
- Sponsor
- Pfizer
Paraganglioma, Pheochromocytoma
LAnreotide in Metastatic Pheochromocytoma / PARAganglioma (LAMPARA)
The objectives of this study are: To assess the efficacy of lanreotide given every 4 weeks in participants with advanced or metastatic paraganglioma/ pheochromocytoma.
- Trial name
- LAMPARA (NCT03946527)
- Testing
- Lanreotide
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Antonio Fojo
Metastatic Uveal Melanoma
Nivolumab Plus Relatlimab in Patients With Metastatic Uveal Melanoma
The purpose of this research is to test if a combination treatment of nivolumab and relatlimab will result in tumor reduction in patients with metastatic uveal melanoma.
- Trial name
- NCT04552223
- Testing
- Nivolumab, Relatlimab
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Jose Lutzky, MD
Unresectable or Metastatic Melanoma
A Study of ST-1898 for Unresectable or Metastatic Melanoma
ST-1898 is a receptor tyrosine kinase (RTK) inhibitor for multi-targets, especially for VEGFR2, c-MET, AXL, PDGFRA, RET, KIT etc.
- Trial name
- NCT06359860
- Testing
- ST-1898 tablets
- Where
- China
- Volunteers
- 64 people
- Sponsor
- Beijing Scitech-Mq Pharmaceuticals Limited
Metastatic Malignant Solid Neoplasm, Metastatic Melanoma
Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
This phase I trial studies the side effects and best dose of modified immune cells (IL13Ralpha2 CAR T cells) after a chemotherapy conditioning regimen for the treatment of patients with stage IIIC or IV melanoma or solid tumors…
- Conditions
- Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IV Cutaneous Melanoma AJCC v8
- Trial name
- NCT04119024
- Testing
- Biopsy, Biospecimen Collection, Computed Tomography
- Where
- 3 sites in United States
- Volunteers
- 18 people
- Sponsor
- Anusha Kalbasi
Breast Cancer, Colon Cancer
Copper Cu 64 Anti-CEA Monoclonal Antibody M5A PET in Diagnosing Patients With CEA Positive Cancer
This pilot clinical trial studies copper Cu 64 anti-carcinoembryonic antigen (CEA) monoclonal antibody M5A positron emission tomography (PET) in diagnosing patients with CEA positive cancer.
- Conditions
- Breast Cancer, Colon Cancer, Extrahepatic Bile Duct Cancer, Gallbladder Cancer
- Trial name
- NCT02293954
- Testing
- radionuclide imaging, positron emission tomography, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- City of Hope Medical Center
Melanoma (Skin)
Combination Chemotherapy With or Without Interleukin-2 and Interferon Alfa in Treating Patients With Metastatic Melanoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Interleukin-2 may stimulate a person's white blood cells to kill melanoma cells.
- Trial name
- NCT00003027
- Testing
- aldesleukin, filgrastim, recombinant interferon alfa
- Where
- 94 sites in United States
- Volunteers
- 482 people
- Sponsor
- Eastern Cooperative Oncology Group
Metastatic Melanoma
Dendritic Cells (DC) Vaccine for Metastatic Melanoma
The purpose of this study is to determine what effect using an experimental tumor vaccine (a substance or group of substances meant to cause the immune system to respond to a tumor) made using patients' own tumor cells and blood…
- Trial name
- NCT01042366
- Testing
- Vaccination
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- John Kirkwood
Melanoma Neoplasms
Assessment of Circulating Tumor Cells and microRNAs in Patients With Metastatic Non-cutaneous Melanoma
the study aims to implement new approaches for the identification of circulating tumor cells and circulating microRNAs, which aim to silence the expression of genes and thus prevent the production of proteins in patients with…
- Trial name
- NCT06863870
- Where
- Italy
- Volunteers
- 35 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Melanoma, Urothelial Carcinoma
A RC198 Study in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors
Safety study of RC198 in Subjects with Solid Tumors.
- Conditions
- Melanoma, Urothelial Carcinoma, Renal Cell Carcinoma, Non-small Cell Lung Cancer
- Trial name
- NCT05867303
- Testing
- RC198 Injection
- Where
- 5 sites in Australia, China
- Volunteers
- 48 people
- Sponsor
- RemeGen Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.